Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17016772 | 1.00 | HPGD (0.32) | HPGDOPRL1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL17016931 | 0.95 | FPR2 (0.32) | HPGDCNR1CNR2 | |
| SCHEMBL17021101 | 0.95 | FPR2 (0.32) | HPGDCNR1CNR2 | |
| SCHEMBL17016752 | 0.93 | HPGD (0.31) | HPGDOPRL1 | |
| SCHEMBL17021074 | 0.93 | HPGD (0.32) | HPGDOPRL1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL17016774 | 0.93 | HPGD (0.32) | HPGDOPRL1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL11940767 | 0.89 | OPRL1 (0.32) | HPGDOPRL1KDM1ACNR1CNR2 | |
| SCHEMBL15803731 | 0.87 | HPGD (0.35) | HPGDOPRL1KDM1ACNR1CNR2 | |
| SCHEMBL13322092 | 0.86 | OPRL1 (0.30) | OPRL1 | |
| SCHEMBL3911928 | 0.85 | OPRL1 (0.32) | HPGDOPRL1KDM1ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9404040-B2 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | PYM1, CXCR1, LEO1 | HPGD 4702/4885OPRL1 1404/4885HTR1A 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.